Last reviewed · How we verify
CNGRC peptide-TNF alpha conjugate
CNGRC peptide-TNF alpha conjugate is a Biologic drug developed by European Organisation for Research and Treatment of Cancer - EORTC. It is currently in Phase 1 development.
At a glance
| Generic name | CNGRC peptide-TNF alpha conjugate |
|---|---|
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CNGRC peptide-TNF alpha conjugate CI brief — competitive landscape report
- CNGRC peptide-TNF alpha conjugate updates RSS · CI watch RSS
- European Organisation for Research and Treatment of Cancer - EORTC portfolio CI
Frequently asked questions about CNGRC peptide-TNF alpha conjugate
What is CNGRC peptide-TNF alpha conjugate?
CNGRC peptide-TNF alpha conjugate is a Biologic drug developed by European Organisation for Research and Treatment of Cancer - EORTC.
Who makes CNGRC peptide-TNF alpha conjugate?
CNGRC peptide-TNF alpha conjugate is developed by European Organisation for Research and Treatment of Cancer - EORTC (see full European Organisation for Research and Treatment of Cancer - EORTC pipeline at /company/european-organisation-for-research-and-treatment-of-cancer-eortc).
What development phase is CNGRC peptide-TNF alpha conjugate in?
CNGRC peptide-TNF alpha conjugate is in Phase 1.